Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 121

Sponsor: Evommune, Inc.

Summary

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Eligibility Criteria

Inclusion Criteria: * Chronic AD that has been present for ≥6 months * Validated-Investigator's Global Assessment score of ≥3 * EASI of ≥16 * BSA of AD involvement of ≥10% Exclusion Criteria: * Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening * Use of certain medications * Presence of skin comorbidities or other condition(s) that may interfere with study assessments * Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07150845). StuddyBuddy aggregates publicly available trial information.